Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions

Serum and Pulmonary Uric Acid in Pulmonary Arterial Hypertension

Laurent Savale, Satoshi Akagi, Ly Tu, Amélie Cumont, Raphaël Thuillet, Carole Phan, Benjamin Le Vely, Nihel Berrebeh, Alice Huertas, Xavier Jaïs, Vincent Cottin, Ari Chaouat, Cécile Tromeur, Athénaïs Boucly, Etienne Marie Jutant, Olaf Mercier, Elie Fadel, David Montani, Olivier Sitbon, Marc Humbert, Yuichi Tamura, Christophe Guignabert
European Respiratory Journal 2021; DOI: 10.1183/13993003.00332-2020
Laurent Savale
1Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
2INSERM UMR_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
3Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Laurent Savale
Satoshi Akagi
1Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
2INSERM UMR_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Satoshi Akagi
Ly Tu
1Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
2INSERM UMR_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amélie Cumont
1Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
2INSERM UMR_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raphaël Thuillet
1Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
2INSERM UMR_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carole Phan
1Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
2INSERM UMR_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin Le Vely
1Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
2INSERM UMR_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nihel Berrebeh
1Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
2INSERM UMR_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alice Huertas
1Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
2INSERM UMR_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
3Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alice Huertas
Xavier Jaïs
1Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
2INSERM UMR_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
3Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincent Cottin
4Université Claude-Bernard Lyon 1, Hôpital Louis-Pradel, service de pneumologie, Centre de référence national des maladies pulmonaires rares, UMR154, Lyon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vincent Cottin
Ari Chaouat
5Université de Lorraine, Département de pneumologie, CHRU de Nancy; Inserm U1116, Vandœuvre-lès-Nancy, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ari Chaouat
Cécile Tromeur
6European Brittany University, Brest, France
7Department of Internal Medicine and Chest Diseases, University Hospital Centre La Cavale Blanche, Brest, France
8Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), EA 3878, CIC INSERM 1412, Brest, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Athénaïs Boucly
1Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
2INSERM UMR_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
3Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Etienne Marie Jutant
1Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
2INSERM UMR_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
3Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olaf Mercier
1Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
2INSERM UMR_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
9Department of Thoracic and Vascular Surgery and Heart-Lung Transplantation, Hôpital Marie Lannelongue, Le Plessis Robinson, France, Groupe Hospitalier Paris Saint Joseph
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elie Fadel
1Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
2INSERM UMR_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
9Department of Thoracic and Vascular Surgery and Heart-Lung Transplantation, Hôpital Marie Lannelongue, Le Plessis Robinson, France, Groupe Hospitalier Paris Saint Joseph
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Montani
1Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
2INSERM UMR_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
3Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David Montani
Olivier Sitbon
1Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
2INSERM UMR_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
3Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Olivier Sitbon
Marc Humbert
1Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
2INSERM UMR_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
3Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marc Humbert
Yuichi Tamura
1Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
2INSERM UMR_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
10Pulmonary Hypertension Center, International University of Health and Welfare Mita Hospital, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christophe Guignabert
1Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
2INSERM UMR_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Rationale Earlier studies have suggested an association between uric acid (UA) and pulmonary arterial hypertension (PAH) severity, but it remains unknown whether UA contributes to the disease pathogenesis.

Objectives To study the prognostic values of circulating UA at era of current management of PAH and investigate the role of UA in the pulmonary vascular remodelling.

Methods Serum UA levels were determined in idiopathic, heritable, or anorexigen PAH at baseline and first re-evaluation in the French PAH registry. We studied protein levels of xanthine oxidase (XO) and the URATv1 transporter in lungs of control and PAH patients and of monocrotaline (MCT) and sugen/hypoxia (SuHx) rats. Functional studies were performed using human pulmonary artery smooth muscle cells (PA-SMCs) and two animal models of pulmonary hypertension (PH).

Results High serum UA levels are associated with a poor prognosis at first follow-up, but not at baseline. Both the generating enzyme XO and URATv1 are upregulated in the wall of remodelled pulmonary arteries in iPAH patients and MCT and SuHx rats. High UA concentrations promote a mild increase in cell growth in iPAH PA-SMCs, but not in control PA-SMCs. Consistent with these observations, we demonstrate that oxonic acid-induced hyperuricemia did not aggravate MCT-induced PH in rats. Finally, we show that chronic treatments of MCT and SuHx rats with benzbromarone mildly attenuate pulmonary vascular remodelling.

Conclusions UA levels in iPAH patients is associated with impaired clinical and hemodynamic profile and might be used as a noninvasive indicator of clinical prognostic during follow-up. Our findings also indicate that metabolism of UA is disturbed in remodelled pulmonary vascular walls in both experimental and human PAH.

Footnotes

This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Conflict of interest: Dr. Funke-Chambour reports grants from roche, grants and personal fees from Boehringer Ingelheim, outside the submitted work;. Dr. Funke-Chambour reports grants from roche, grants and personal fees from Boehringer Ingelheim, outside the submitted work;.

Conflict of interest: Dr. Savale reports grants, personal fees and non-financial support from Actelion, personal fees and non-financial support from MSD, personal fees and non-financial support from Bayer, grants, personal fees and non-financial support from GSK, outside the submitted work;.

Conflict of interest: Dr. Akagi has nothing to disclose.

Conflict of interest: Dr. TU has nothing to disclose.

Conflict of interest: Dr. Cumont has nothing to disclose.

Conflict of interest: Dr. Thuillet has nothing to disclose.

Conflict of interest: Dr. Phan has nothing to disclose.

Conflict of interest: Dr. LE VELY has nothing to disclose.

Conflict of interest: Dr. BERREBEH has nothing to disclose.

Conflict of interest: Dr. HUERTAS has nothing to disclose.

Conflict of interest: Dr. JAIS reports grants and personal fees from Actelion, grants and personal fees from MSD, grants from Bayer, outside the submitted work;.

Conflict of interest: Dr. Cottin has nothing to disclose.

Conflict of interest: Dr. Chaouat has nothing to disclose.

Conflict of interest: Dr. TROMEUR has nothing to disclose.

Conflict of interest: Dr. Boucly reports personal fees and non-financial support from Actelion, personal fees from MSD, outside the submitted work;.

Conflict of interest: Dr. Jutant has nothing to disclose.

Conflict of interest: Dr. Mercier has nothing to disclose.

Conflict of interest: Dr. Fadel has nothing to disclose.

Conflict of interest: Dr. MONTANI reports grants and personal fees from Actelion, grants and personal fees from Bayer, personal fees from GSK, personal fees from Pfizer, personal fees from MSD, personal fees from Chiesi, outside the submitted work.

Conflict of interest: Dr. SITBON reports grants, personal fees and non-financial support from Actelion Pharmaceuticals, personal fees from Acceleron Pharmaceuticals, grants, personal fees and non-financial support from Bayer, grants, personal fees and non-financial support from MSD, grants from GlaxoSmithKline, personal fees from Gossamer Bio, personal fees from Ferrer, outside the submitted work;.

Conflict of interest: Dr. Humbert reports personal fees from Actelion, grants and personal fees from Bayer, grants and personal fees from GSK, personal fees from Merck, from United Therapeutics, personal fees from Acceleron, outside the submitted work.

Conflict of interest: Dr. Tamoura has nothing to disclose.

Conflict of interest: Dr. Guignabert has nothing to disclose.

This is a PDF-only article. Please click on the PDF link above to read it.

  • Received February 15, 2020.
  • Accepted December 20, 2020.
  • ©The authors 2021. For reproduction rights and permissions contact permissions{at}ersnet.org
PreviousNext
Back to top
View this article with LENS
Vol 62 Issue 6 Table of Contents
European Respiratory Journal: 62 (6)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Serum and Pulmonary Uric Acid in Pulmonary Arterial Hypertension
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Serum and Pulmonary Uric Acid in Pulmonary Arterial Hypertension
Laurent Savale, Satoshi Akagi, Ly Tu, Amélie Cumont, Raphaël Thuillet, Carole Phan, Benjamin Le Vely, Nihel Berrebeh, Alice Huertas, Xavier Jaïs, Vincent Cottin, Ari Chaouat, Cécile Tromeur, Athénaïs Boucly, Etienne Marie Jutant, Olaf Mercier, Elie Fadel, David Montani, Olivier Sitbon, Marc Humbert, Yuichi Tamura, Christophe Guignabert
European Respiratory Journal Jan 2021, 2000332; DOI: 10.1183/13993003.00332-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Serum and Pulmonary Uric Acid in Pulmonary Arterial Hypertension
Laurent Savale, Satoshi Akagi, Ly Tu, Amélie Cumont, Raphaël Thuillet, Carole Phan, Benjamin Le Vely, Nihel Berrebeh, Alice Huertas, Xavier Jaïs, Vincent Cottin, Ari Chaouat, Cécile Tromeur, Athénaïs Boucly, Etienne Marie Jutant, Olaf Mercier, Elie Fadel, David Montani, Olivier Sitbon, Marc Humbert, Yuichi Tamura, Christophe Guignabert
European Respiratory Journal Jan 2021, 2000332; DOI: 10.1183/13993003.00332-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
  • Info & Metrics
  • PDF

Subjects

  • Pulmonary vascular disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Lung volumes and survival in chronic lung allograft dysfunction
  • EBUS-guided cryobiopsies in peripheral pulmonary lesions
  • Safety of formoterol in asthma clinical trials
Show more Original Article

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society